Biocement / MICP Self-Healing Bioconcrete (WO2020229797A1)

Product · Materials Science

Product · InnDex 28 · Evidence provided · High specification risk

Bacteria-embedded concrete that self-heals cracks via calcium carbonate precipitation when water infiltrates.

Biocement embeds anaerobic bacteria into fresh concrete; when cracks form and water enters, the bacteria trigger microbially induced calcium carbonate precipitation (MICP) to seal fractures autonomously. It targets chloride ingress and water permeability in marine and reinforced concrete structures. The LJMU formulation lacks field deployment or independent third-party validation, though the broader MICP field shows pilot credibility (M25 motorway trials, lab footbridges).

Biocement embeds anaerobic bacteria into fresh concrete so that when cracks form and water infiltrates, microbially induced calcium carbonate precipitation seals the fracture autonomously — targeting chloride ingress and water permeability in marine and reinforced structures without topical maintenance intervention. The MICP mechanism is scientifically credible and broader field activity gives the concept genuine pilot-level legitimacy: M25 motorway trials and lab-scale footbridges in the wider research community provide supportive context, though they use different formulations and organisms from the LJMU patent. The critical commercial problem is that the specific patent this record documents has ceased at LJMU, with no active commercialisation pathway or licensed manufacturer identified, which means the first question for a specifier is not performance but procurement: this product is currently unavailable. Even setting that aside, bacterial viability in fresh concrete depends on pH, moisture, and temperature thresholds that are not yet standardised, healing speed and completeness under structural load at real scale is uncharacterised, and building codes do not recognise bio-healed cracks as equivalent to pre-crack condition or traditional repair. The concept is worth monitoring as the broader MICP field matures, but the LJMU-specific route has no clear path to market.

Strengths

• Autonomous crack repair without human intervention or topical application, extending structure lifespan.
• Reduces chloride ingress and water permeability in marine and wet environments without additional membranes.
• Potential to lower whole-life maintenance and repair costs if healing persists across multiple crack cycles.
• Bio-based mechanism may reduce embodied carbon versus traditional repair or protective coatings.

Considerations

• Bacterial viability in concrete is unpredictable; dormancy and reactivation depend on pH, moisture, and temperature thresholds not yet standardized. (high)
• Healing speed and completeness are unknown at structural scale; laboratory results do not guarantee closure of large or dynamic cracks under load. (high)
• Requires controlled fresh concrete conditions to embed and preserve bacteria; incompatible with aggressive batching, curing, or harsh site conditions. (moderate)
• Cannot be reliably inspected or verified post-pour; no non-destructive test method exists to confirm bacterial presence or healing readiness. (moderate)

Risks

• Patent ceased at LJMU; no active commercialization pathway or licensed manufacturer identified. Product readiness and availability are unclear. (critical)
• No peer-reviewed evidence of field performance at scale; laboratory footbridges and M25 trials use different formulations or organisms, limiting transferability. (high)
• Long-term durability unproven: unclear whether calcium carbonate seal remains intact over 20+ years, under wet–dry cycles, or under sustained structural strain. (high)
• Regulatory path undefined; building codes do not yet recognize bio-healed cracks as equivalent to pre-crack concrete or traditional repairs. (high)
• Risk of bacterial leachate or unintended metabolic byproducts in groundwater or indoor air; environmental fate not characterized. (moderate)

Performance

• Capillary water absorption reduction (CEMIII): 40% (lab)
• Chloride migration reduction (CEMIII): 50% (lab)
• Compressive strength change (CEMI): -5% (negative)
• Patent status: Ceased (no active IP)

Reality check

Patent WO2020229797A1 now ceased status. Lab data provided for CEMIII blends show genuine improvements in capillary absorption (40% reduction) and chloride migration (50% reduction coefficient). However: (1) compressive strength in CEMI formulations declined ~5%, directly contradicting candidate's claim of '40–60% strength gain'; (2) cited figures ('48% permeability reduction', '2mm crack sealing') do not appear verbatim in patent text; (3) no peer-reviewed publications found validating this formulation at structural scale; (4) organism viability, long-term dormancy, and activation reliability in field conditions not demonstrated. Broader MICP literature is growing but heterogeneous; this specific work lacks independent corroboration.

#self-healing #bioconcrete #durability #MICP #marine #crack-sealing

Source